2016
Nivolumab and Pembrolizumab for Non–Small Cell Lung Cancer
Morgensztern D, Herbst RS. Nivolumab and Pembrolizumab for Non–Small Cell Lung Cancer. Clinical Cancer Research 2016, 22: 3713-3717. PMID: 27252413, DOI: 10.1158/1078-0432.ccr-15-2998.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungClinical Trials, Phase I as TopicHumansLung NeoplasmsNivolumabPrognosisProgrammed Cell Death 1 ReceptorRandomized Controlled Trials as TopicTreatment OutcomeConceptsCheckpoint inhibitorsClinical trialsAdvanced stage non-small lung cancerDeath-1 checkpoint inhibitorsLarge randomized clinical trialsNon-small lung cancerSecond-line docetaxelSurvivors 3 yearsBest supportive careSubset of patientsRandomized clinical trialsOverall survivalSupportive careCombination therapyLung cancerModest benefitPatientsPhase IImmunotherapyReliable predictorTherapyInhibitorsTrialsTreatmentNivolumab
2009
Beyond Doublet Chemotherapy for Advanced Non–Small-Cell Lung Cancer: Combination of Targeted Agents with First-Line Chemotherapy
Herbst RS, Lynch TJ, Sandler AB. Beyond Doublet Chemotherapy for Advanced Non–Small-Cell Lung Cancer: Combination of Targeted Agents with First-Line Chemotherapy. Clinical Lung Cancer 2009, 10: 20-27. PMID: 19289368, DOI: 10.3816/clc.2009.n.003.Peer-Reviewed Original ResearchConceptsBest supportive careOverall survivalMetastatic NSCLCLung cancerAdvanced non-small cell lung cancerNon-small cell lung cancerPhase III clinical trialsPlatinum-based doubletsAddition of bevacizumabFirst-line chemotherapyPlatinum-based regimensProgression-free survivalFirst-line treatmentCell lung cancerOverall patient survivalTyrosine kinase inhibitorsInhibition of componentsMatrix metalloproteinase inhibitorsDoublet chemotherapySystemic chemotherapyMedian survivalSupportive careMost patientsTargeted agentsChemotherapeutic regimens
2008
Advances in the Treatment of Metastatic Non–Small-Cell Lung Cancer With Chemotherapy and Targeted Agents
Lilenbaum R, Herbst R. Advances in the Treatment of Metastatic Non–Small-Cell Lung Cancer With Chemotherapy and Targeted Agents. Clinical Pulmonary Medicine 2008, 15: 352-358. DOI: 10.1097/cpm.0b013e31818cd61f.Peer-Reviewed Original ResearchCell lung cancerMetastatic NSCLCOverall survivalLung cancerPatient outcomesAdvanced metastatic NSCLCThird-line settingBest supportive careProgression-free survivalAntiangiogenic agent bevacizumabOverall patient survivalPatient selection criteriaOngoing clinical trialsEpidermal growth factor receptorGrowth factor receptorRefractory settingAgent bevacizumabSupportive careTargeted agentsOptimal therapyChemotherapeutic regimensPatient survivalClinical trialsResponse rateMaximal benefit
2006
Efficacy and safety of gefitinib in chemonaive patients with advanced non-small cell lung cancer treated in an Expanded Access Program
Govindan R, Natale R, Wade J, Herbst R, Krebs A, Reiling R, Hensing T, Wozniak A, Belani CP, Kelly K, Ochs J. Efficacy and safety of gefitinib in chemonaive patients with advanced non-small cell lung cancer treated in an Expanded Access Program. Lung Cancer 2006, 53: 331-337. PMID: 16797779, DOI: 10.1016/j.lungcan.2006.04.013.Peer-Reviewed Original ResearchConceptsAdvanced non-small cell lung cancerNon-small cell lung cancerExpanded Access ProgramCell lung cancerLung cancerRecurrent advanced non-small cell lung cancerEpidermal growth factor receptor tyrosine kinase inhibitor gefitinibNumerous clinical guidelinesSafety of gefitinibBest supportive careCommon adverse eventsPartial response ratePoor performance statusRetrospective chart reviewMajority of patientsTyrosine kinase inhibitor gefitinibFavorable toxicity profileAccess programKinase inhibitor gefitinibPrevious chemotherapyStable diseaseSubsequent chemotherapyChemonaive patientsAdverse eventsChart review